↓ Skip to main content

Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial

Overview of attention for article published in BMC Cancer, May 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Readers on

mendeley
12 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial
Published in
BMC Cancer, May 2022
DOI 10.1186/s12885-022-09644-8
Pubmed ID
Authors

Cunliang Wang, Shouhui Zhu, Chuanwang Miao, Yu Wang, Jiazhen Chen, Shuanghu Yuan, Xudong Hu

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 2 17%
Lecturer 1 8%
Unspecified 1 8%
Other 1 8%
Student > Master 1 8%
Other 0 0%
Unknown 6 50%
Readers by discipline Count As %
Medicine and Dentistry 3 25%
Unspecified 1 8%
Psychology 1 8%
Nursing and Health Professions 1 8%
Unknown 6 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 September 2022.
All research outputs
#15,623,687
of 23,230,825 outputs
Outputs from BMC Cancer
#4,184
of 8,419 outputs
Outputs of similar age
#249,054
of 441,751 outputs
Outputs of similar age from BMC Cancer
#116
of 292 outputs
Altmetric has tracked 23,230,825 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,419 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 441,751 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 292 others from the same source and published within six weeks on either side of this one. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.